Restart Life Sciences Corp. (NMLSF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Restart Life Sciences Corp. (NMLSF) trades at $0.06279. Restart Life Sciences Corp. is a biotechnology company based in Vancouver, Canada, primarily focused on the research and development of psilocybin. Market cap: $2.29M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for NMLSF: NMLSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NMLSF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on NMLSF.
How is this calculated? →Restart Life Sciences Corp. (NMLSF) Healthcare & Pipeline Overview
Restart Life Sciences Corp. is a biotechnology company headquartered in Vancouver, Canada, specializing in the exploration and advancement of psilocybin. The firm develops therapeutic treatments and diagnostic instruments primarily targeting neuroinflammatory conditions, positioning itself within the emerging psychedelic medicine and neuroscience sectors. Established in 2004, it operates on the OTC Other market.
What Is the Investment Thesis for NMLSF?
Restart Life Sciences Corp. presents an investment profile centered on its pioneering work in psilocybin-based therapeutics and diagnostics for neuroinflammatory conditions. The company's core value driver lies in the potential of psilocybin, an area gaining increasing scientific and regulatory interest for its therapeutic applications, particularly in mental health and neurological disorders. Successful clinical trials and subsequent regulatory approvals for its therapeutic treatments or diagnostic instruments would serve as significant growth catalysts, potentially unlocking substantial market opportunities in a sector with unmet medical needs. With a reported market capitalization of $2.29M, the company is in its nascent stages, indicating a high-risk, high-reward profile typical of early-stage biotechnology ventures. Its negative beta of -0.81 suggests a potential inverse correlation with broader market movements, though this metric can be highly volatile and less indicative for micro-cap, developmental-stage companies. Key risks include the inherent challenges of drug development, such as trial failures, regulatory hurdles, and intense competition, compounded by the speculative nature and limited liquidity often associated with OTC-listed entities. The absence of a dividend yield underscores its focus on reinvesting capital into research and development.
Based on FMP financials and quantitative analysis
NMLSF Key Highlights
Primary focus on psilocybin research and development for neuroinflammatory conditions, positioning the company in an emerging therapeutic area.
- Operates as a biotechnology firm, established on October 27, 2004, indicating over two decades of corporate existence, though its current focus may be more recent.
- Trades on the OTC Other market, which typically signifies an early-stage company with limited public disclosure and potentially lower liquidity compared to major exchanges.
- Reported market capitalization of $2.29M, reflecting its developmental stage and micro-cap status within the biotechnology sector.
- Negative beta of -0.81, suggesting a historical tendency to move inversely to the broader market, though this can be highly variable for small, speculative stocks.
Who Are NMLSF's Competitors?
NMLSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NMLSF's Key Strengths?
Niche focus on psilocybin and neuroinflammatory conditions, addressing an area with unmet medical needs.
- Dual approach of developing both therapeutic treatments and diagnostic instruments, potentially offering comprehensive solutions.
- Early-stage positioning in the emerging field of psychedelic medicine, allowing for significant growth if successful.
- Established in 2004, indicating a foundational history in the biotechnology sector.
What Are NMLSF's Weaknesses?
Operates on the OTC Other tier, implying limited public disclosure and potential challenges in investor confidence and liquidity.
- Reported market capitalization of $2.29M, indicating a very early stage of commercial development and high reliance on future funding.
- High inherent risks associated with biotechnology R&D, including potential for clinical trial failures and lengthy regulatory processes.
- Unknown disclosure status on the OTC market, which can hinder investor due diligence and transparency.
What Could Drive NMLSF Stock Higher?
**Successful Completion of Preclinical Studies for Psilocybin Therapeutics.** Positive outcomes from preclinical research demonstrating the safety and efficacy of Restart Life Sciences' psilocybin compounds in animal models or in vitro studies could pave the way for human clinical trials.
- **Initiation of Phase 1 Clinical Trials for a Neuroinflammatory Treatment.** Gaining regulatory approval to begin human clinical trials would be a significant milestone, validating the company's research and moving it closer to potential commercialization.
- **Advancements in Diagnostic Instrument Development.** Continued progress in the development and validation of diagnostic instruments for neuroinflammatory conditions, leading to prototypes or early testing, could attract partnerships or further investment.
- **Securing Strategic Partnerships or Licensing Agreements.** Announcing collaborations with larger pharmaceutical companies or research institutions could provide crucial funding, expertise, and validation for Restart Life Sciences' programs.
What Are the Key Risks for NMLSF?
Financial-distress signal — its Altman Z-Score of -35.46 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- **Clinical Trial Failures.** The inherent risk in biotechnology is that therapeutic candidates may fail to demonstrate efficacy or safety in human clinical trials, leading to project termination and significant financial losses.
- **Regulatory Setbacks.** Obtaining regulatory approvals for novel psilocybin-based therapies and diagnostic instruments is a complex and lengthy process, with potential for delays, additional requirements, or outright rejection.
- **Funding Challenges.** As an early-stage biotechnology company with a market capitalization of $2.29M, Restart Life Sciences faces ongoing challenges in securing sufficient capital to fund its extensive and costly research and development activities.
- **Intense Competition.** The biotechnology and psychedelic medicine sectors are highly competitive, with numerous companies vying for market share and intellectual property, potentially limiting Restart Life Sciences' future commercial success.
- **OTC Market Volatility and Illiquidity.** Trading on the OTC Other tier exposes investors to high stock price volatility, wide bid-ask spreads, and limited liquidity, making it difficult to buy or sell shares efficiently.
What Are the Growth Opportunities for NMLSF?
- Growth opportunity 1: **Advancement and Commercialization of Psilocybin Therapeutics for Neuroinflammatory Conditions.** The market for psychedelic-assisted therapies is projected to grow significantly, with psilocybin showing promise for various neurological and psychiatric disorders. Restart Life Sciences' specific focus on neuroinflammatory conditions positions it to address a distinct and underserved patient population. Successful progression through clinical trials, demonstrating efficacy and safety, could lead to regulatory approvals and market entry. The global neuroinflammatory disease market is substantial, potentially reaching tens of billions of dollars, and NMLSF's innovative approach could capture a meaningful share if its therapies prove superior or complementary to existing treatments. The timeline for such growth is contingent on trial success and regulatory pathways, typically spanning several years.
- Growth opportunity 2: **Development and Market Penetration of Diagnostic Instruments.** Beyond therapeutics, Restart Life Sciences is developing diagnostic instruments for neuroinflammatory conditions. Accurate and early diagnosis is critical for effective treatment and disease management, representing a significant market opportunity. The global market for neurological diagnostic devices is expanding, driven by an aging population and increasing prevalence of neurological disorders. NMLSF's specialized instruments could offer improved precision or novel biomarkers, providing a competitive edge. Commercialization of these instruments could provide an earlier revenue stream compared to drug development, which has longer timelines. The success of these diagnostics would depend on their clinical utility, regulatory clearance, and adoption by healthcare providers.
- Growth opportunity 3: **Expansion into Additional Neuroinflammatory Indications.** The umbrella of neuroinflammatory conditions is broad, encompassing various diseases with distinct pathologies. Restart Life Sciences' initial success in one specific neuroinflammatory indication could pave the way for expanding its research and development efforts into other related conditions. This strategy allows the company to leverage its existing scientific expertise and platform technologies across multiple therapeutic areas, diversifying its pipeline and potential revenue streams. Each new indication represents a distinct market opportunity, potentially adding billions to the addressable market. This expansion would be a long-term growth driver, requiring further preclinical and clinical development.
- Growth opportunity 4: **Strategic Partnerships and Collaborations.** For an early-stage biotechnology company like Restart Life Sciences, forming strategic partnerships with larger pharmaceutical companies or academic institutions can be a crucial growth driver. Such collaborations can provide access to additional funding, advanced research capabilities, manufacturing expertise, and established commercialization channels. These partnerships can accelerate drug development timelines, reduce financial risk, and enhance market access. Licensing agreements or co-development deals could provide significant upfront payments and milestone revenues, bolstering the company's financial position and validating its scientific approach. These opportunities are ongoing and can materialize at various stages of product development.
- Growth opportunity 5: **Leveraging Intellectual Property and Patent Protection.** As a biotechnology company focused on novel therapies and diagnostics, the development and protection of intellectual property (IP) are paramount. Securing robust patents for its psilocybin formulations, therapeutic methods, and diagnostic instruments will provide Restart Life Sciences with a competitive moat, preventing competitors from replicating its innovations. A strong IP portfolio enhances the company's valuation, attracts potential partners, and secures market exclusivity for its products upon approval. The ongoing process of filing and defending patents is a continuous growth opportunity that underpins the long-term commercial viability and profitability of its offerings in the highly competitive healthcare sector.
- Growth opportunity 6: **Regulatory Milestones and Market Approvals.** The achievement of key regulatory milestones, such as successful Phase 1, 2, or 3 clinical trial results and ultimately, marketing authorization from health authorities like the FDA or Health Canada, represents a critical growth opportunity. Each successful step validates the scientific and commercial potential of Restart Life Sciences' products. Market approvals would enable the company to commercialize its therapeutic treatments and diagnostic instruments, transitioning from a research-focused entity to a revenue-generating one. These events are typically associated with significant increases in company valuation and investor confidence, marking the culmination of extensive R&D efforts and opening doors to direct market engagement.
What Threats Does NMLSF Face?
- Intense competition from established pharmaceutical companies and other biotech firms in both neuroscience and psychedelic research.
- Significant regulatory hurdles and lengthy approval processes for both novel drugs and medical devices.
- Reliance on successful clinical trial outcomes; failures could lead to substantial financial losses and project termination.
- Challenges in securing adequate funding for prolonged research and development, especially as an OTC-listed entity.
What Are NMLSF's Competitive Advantages?
- Specialized focus on psilocybin and neuroinflammatory conditions, creating a niche expertise.
- Potential for proprietary research and intellectual property surrounding psilocybin formulations and applications.
- Development of unique diagnostic instruments that could offer superior detection or monitoring capabilities.
- Early-mover advantage in specific sub-segments of the psychedelic medicine market for neuroinflammation.
What Does NMLSF Do?
Restart Life Sciences Corp., established on October 27, 2004, in Vancouver, Canada, operates as a biotechnology firm dedicated to the exploration and advancement of psilocybin. The company's strategic focus encompasses the development of both therapeutic treatments and diagnostic instruments, specifically designed to address neuroinflammatory conditions. From its inception, Restart Life Sciences has positioned itself within the burgeoning field of psychedelic medicine, aiming to leverage the potential of psilocybin for novel medical applications. While the company's early history likely involved foundational research and strategic planning typical of a nascent biotech, its current operations are centered on bringing these innovative solutions to market. The emphasis on neuroinflammatory conditions highlights a commitment to addressing a complex and often underserved area of healthcare, where traditional treatments may have limitations. By pursuing both therapeutic interventions and diagnostic tools, Restart Life Sciences aims to offer a comprehensive approach to managing these challenging conditions. Its operations, primarily based in Canada, reflect a regional hub for biotechnology innovation, though the potential impact of its research could extend globally. As an OTC-listed entity, the company is in an earlier stage of development compared to larger, exchange-listed pharmaceutical firms, focusing on specialized research and the rigorous process of drug and device development within a niche market.
What Products and Services Does NMLSF Offer?
- Conduct research and development focused on psilocybin.
- Develop therapeutic treatments for neuroinflammatory conditions.
- Create diagnostic instruments specifically for neuroinflammatory conditions.
- Explore the potential of psychedelic compounds for medical applications.
- Operate within the biotechnology sector, specializing in neuroscience.
- Engage in the rigorous process of preclinical and clinical development for novel healthcare solutions.
How Does NMLSF Make Money?
- Future revenue generation from the sale of approved psilocybin-based therapeutic treatments.
- Potential income from the commercialization and sales of diagnostic instruments for neuroinflammatory conditions.
- Possible licensing agreements or partnerships with larger pharmaceutical companies for product development or commercialization rights.
- Reliance on capital raises and grants to fund ongoing research and development activities during its early-stage phase.
What Industry Does NMLSF Operate In?
Restart Life Sciences Corp. operates within the dynamic and research-intensive biotechnology industry, specifically targeting the emerging field of psychedelic medicine and neuroinflammatory conditions. The broader biotechnology sector is characterized by significant R&D investment, long development cycles, and high regulatory hurdles, but also offers substantial rewards for successful innovation. Within this landscape, Restart Life Sciences distinguishes itself by focusing on psilocybin, a compound that is increasingly being explored for its therapeutic potential in various neurological and psychiatric disorders. The market for neuroinflammatory treatments is substantial, driven by conditions such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease, which represent significant unmet medical needs. Restart Life Sciences' dual approach of developing both therapeutic treatments and diagnostic instruments positions it to potentially capture value across the patient care continuum. The competitive landscape includes larger pharmaceutical companies with established neuroscience pipelines, as well as a growing number of smaller biotech firms also exploring psychedelic compounds. Restart Life Sciences fits into this niche as an early-stage player aiming to carve out a specialized position through its focused research.
Who Are NMLSF's Key Customers?
- Healthcare providers, including neurologists and psychiatrists, who would prescribe or administer treatments.
- Patients suffering from various neuroinflammatory conditions who would benefit from the company's therapies.
- Hospitals and clinics that would utilize the diagnostic instruments for patient assessment.
- Research institutions and academic centers interested in collaborative studies or licensing the company's technologies.
Company Profile
Restart Life Sciences Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Steve Loutskou. NMLSF has traded publicly since 2011.
How Restart Life Sciences Corp. Is Valued
Restart Life Sciences Corp. carries a market capitalization of $2.29M, placing it in the micro-cap category.
Key Financial Metrics
Return on assets is -39.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -22.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.01 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -18.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Restart Life Sciences Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -35.46 places it in the distress zone, a signal of elevated financial risk.
NMLSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Niche focus on psilocybin and neuroinflammatory conditions, addressing an area with unmet medical needs.
- Dual approach of developing both therapeutic treatments and diagnostic instruments, potentially offering comprehensive solutions.
- Early-stage positioning in the emerging field of psychedelic medicine, allowing for significant growth if successful.
- Established in 2004, indicating a foundational history in the biotechnology sector.
Bear Case
- Operates on the OTC Other tier, implying limited public disclosure and potential challenges in investor confidence and liquidity.
- Reported market capitalization of $2.29M, indicating a very early stage of commercial development and high reliance on future funding.
- High inherent risks associated with biotechnology R&D, including potential for clinical trial failures and lengthy regulatory processes.
- Unknown disclosure status on the OTC market, which can hinder investor due diligence and transparency.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
NMLSF Latest News
No recent news available for NMLSF.
NMLSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NMLSF.
Price Targets
Wall Street price target analysis for NMLSF.
NMLSF MoonshotScore
What does this score mean?
The MoonshotScore rates NMLSF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Steve Loutskou
Chief Executive Officer
Unknown
Track Record: Unknown
NMLSF OTC Market Information
Restart Life Sciences Corp. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges such as the NYSE or NASDAQ, which must meet stringent financial and governance requirements, companies on the OTC Other tier have minimal to no reporting obligations. This tier is typically home to shell companies, distressed companies, or those with limited public information. It differs significantly from the OTCQX Best Market and OTCQB Venture Market, which have higher disclosure standards and financial qualifications, aiming to provide more transparent and liquid trading environments. Investors in OTC Other stocks face unique challenges due to the lack of mandated financial reporting and operational transparency.
- OTC Tier: OTC Other
- **Limited Information & Transparency:** The unknown disclosure status means investors have very little reliable information about the company's financials, operations, and management, making due diligence extremely difficult.
- **Extreme Volatility:** Low trading volume and wide bid-ask spreads inherent to the OTC Other tier can lead to significant and unpredictable price fluctuations.
- **Fraud Risk:** The lack of regulatory oversight and disclosure requirements on this tier makes it more susceptible to fraudulent schemes and pump-and-dump operations.
- **Lack of Liquidity:** Investors may find it challenging to sell shares quickly without incurring substantial losses due to the absence of a robust trading market.
- **Difficulty in Valuation:** Without consistent financial reporting and analyst coverage, accurately assessing the company's intrinsic value is nearly impossible.
- Verify any available corporate filings or press releases directly from the company or third-party sources, if they exist.
- Research the background and legitimacy of the management team, particularly the CEO, Steve Loutskou, for any red flags.
- Investigate the scientific basis and market potential of their psilocybin research and neuroinflammatory treatments.
- Assess the company's capital structure and any reported financing activities, looking for dilution or unsustainable debt.
- Examine any intellectual property claims or patents related to their products to understand potential competitive advantages.
- Consider the regulatory landscape for psilocybin and neuroinflammatory treatments, including potential hurdles and timelines.
- Evaluate the company's operational status and any signs of active research or development, rather than just a shell entity.
- Existence of a professional company website detailing their scientific focus, team, and mission.
- Issuance of legitimate press releases announcing research milestones, partnerships, or corporate updates (even if not regulatory filings).
- Presence of a physical headquarters in Vancouver, Canada, as stated, and any verifiable operational activities there.
- Any verifiable scientific publications or presentations by the company's researchers in reputable journals or conferences.
- Involvement of credible scientific advisors or board members, if such information is made public.
Common Questions About NMLSF (Healthcare)
What does Restart Life Sciences Corp. do?
Restart Life Sciences Corp. is a biotechnology company primarily engaged in the research and development of psilocybin. Its core mission involves creating innovative therapeutic treatments and diagnostic instruments specifically tailored for neuroinflammatory conditions. Established in 2004 and headquartered in Vancouver, Canada, the company operates within the emerging field of psychedelic medicine.
What are the key challenges facing Restart Life Sciences Corp. in the biotechnology sector?
Restart Life Sciences Corp. faces several significant challenges inherent to the biotechnology sector, especially as an early-stage company. A primary challenge is the high risk and capital intensity of drug development, where clinical trial failures are common and can lead to substantial financial losses.
How does Restart Life Sciences Corp.'s focus on psilocybin differentiate it within the neuroinflammatory treatment market?
Restart Life Sciences Corp.'s differentiation stems from its specific focus on psilocybin as a core compound for developing treatments and diagnostics for neuroinflammatory conditions. While many companies in the neuroscience space focus on traditional pharmaceutical approaches, Restart Life Sciences is exploring the therapeutic potential of psychedelics, an area gaining renewed scientific interest for its unique mechanisms of action.
What are the key factors to evaluate for NMLSF?
Evaluate NMLSF on fundamentals, analyst consensus, and risk factors. Restart Life Sciences Corp. presents an investment profile centered on its pioneering work in psilocybin-based therapeutics and diagnostics for neuroinflammatory conditions. Not financial advice.
How frequently does NMLSF data refresh on this page?
NMLSF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NMLSF's recent stock price performance?
Restart Life Sciences Corp. (NMLSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Niche focus on psilocybin and neuroinflammatory conditions, addressing an area with unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NMLSF overvalued or undervalued right now?
Restart Life Sciences Corp. (NMLSF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NMLSF before investing?
Before investing in Restart Life Sciences Corp. (NMLSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information on CEO's background and track record, as well as specific financial metrics beyond market cap and beta, were not provided in the source data and are marked as 'Unknown' or inferred based on general OTC characteristics.
- Competitor information (FMP PEER TICKERS) was not provided, so the 'competitors' array is empty as per instructions.
- Word count requirements were strictly adhered to, which necessitated some inference and elaboration based on the core business description provided.